TECregen pioneers thymus regeneration with a pipeline of differentiated thymopoietic biologics designed to revitalize and expand thymic epithelial cells (TECs) and replenish T-cell populations. Its therapeutic approach targets conditions driven by impaired T-cell responses, aiming to boost immune recovery after transplantation or cytotoxic therapy, promote lifelong immune health, and improve immune surveillance against cancer. The platform also holds promise across broader immunology, oncology, and rare-disease indications. Fresh capital from a CHF 10 million seed financing provides the resources to advance preclinical programs toward first-in-human studies. The company has reinforced its leadership by appointing seasoned biotech executive Dr. Bo Rode Hansen as chairman to guide strategic growth. Backed by a syndicate of specialized life-science investors, TECregen is positioning itself at the forefront of immune-restoration therapeutics. No revenue or user metrics have been disclosed, as the company remains in the preclinical stage.

Total raised

$13M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2026